New combo aims to outsmart recurrent ovarian cancer
NCT ID NCT04034927
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study compares two treatments for women with ovarian, fallopian tube, or peritoneal cancer that has come back after initial therapy. One group gets olaparib alone, the other gets olaparib plus tremelimumab. Olaparib blocks cancer cells from repairing themselves, while tremelimumab helps the immune system attack the cancer. The goal is to see if the combination delays cancer growth better than olaparib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912, United States
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Hartford Hospital
Hartford, Connecticut, 06102, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Women and Infants Hospital
Providence, Rhode Island, 02905, United States
Conditions
Explore the condition pages connected to this study.